Treatment of Ulcerative Colitis
common.study.values.description
“A Study to Investigate How Well ABBV-323 Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy”
Study M15-722 is a Phase 2a study to investigate the efficacy and safety of ABBV-323 in participants with moderate to severe UC who failed prior therapy.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - ABBV-323 Dose A
ABBV-323 Dose A is intravenously (IV) administered.
Drug - ABBV-323 Dose B
ABBV-323 Dose B is administered subcutaneously (SC).
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of ABBV-323 in Subjects With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
common.study.values.clinical-trial-id
NCT03695185
participant.views.study.view.id
e73pje
